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Essentials
• Complement, Toll-like receptors and coagulation cross-
talk in the process of thromboinflammation.
• This is explored in a unique human whole-blood model
of S. aureus bacteremia.
• Coagulation is here shown as a downstream event of
C5a-induced tissue factor (TF) production.
• Combined inhibition of C5 and CD14 efficiently attenu-
ated TF and coagulation.
Summary. Background: There is extensive cross-talk
between the complement system, the Toll-like receptors
(TLRs), and hemostasis. Consumptive coagulopathy is a
hallmark of sepsis, and is often mediated through
increased tissue factor (TF) expression. Objectives: To
study the relative roles of complement, TLRs and TF in
Staphylococcus aureus-induced coagulation. Methods:
Lepirudin-anticoagulated human whole blood was incu-
bated with the three S. aureus strains Cowan, Wood, and
Newman. C3 was inhibited with compstatin, C5 with ecu-
lizumab, C5a receptor 1 (C5aR1) and activated factor XII
with peptide inhibitors, CD14, TLR2 and TF with neu-
tralizing antibodies, and TLR4 with eritoran. Complement
activation was measured by ELISA. Coagulation was
measured according to prothrombin fragment 1 + 2
(PTF1 + 2) determined with ELISA, and TF mRNA,
monocyte surface expression and functional activity were
measured with quantitative PCR, flow cytometry, and
ELISA, respectively. Results: All three strains generated
substantial and statistically significant amounts of C5a,
terminal complement complex, PTF1 + 2, and TF mRNA,
and showed substantial TF surface expression on mono-
cytes and TF functional activity. Inhibition of C5 cleavage
most efficiently and significantly inhibited all six markers
in strains Cowan and Wood, and five markers in New-
man. The effect of complement inhibition was shown to
be completely dependent on C5aR1. The C5 blocking
effect was equally potentiated when combined with
blocking of CD14 or TLR2, but not TLR4. TF block-
ing significantly reduced PTF1 + 2 levels to baseline
levels. Conclusions: S. aureus-induced coagulation in
human whole blood was mainly attributable to C5a-
induced mRNA upregulation, monocyte TF expression,
and plasma TF activity, thus underscoring complement as
a key player in S. aureus-induced coagulation.
Keywords: bacteremia; blood coagulation; complement
system proteins; Staphylococcus aureus; tissue factor;
Toll-like receptor.
Introduction
Sepsis is a critical and potentially lethal syndrome with
an increasing incidence [1]. No specific therapy has been
developed, despite vigorous attempts to do so. Supportive
care has improved survival over the past decades, but
mortality and morbidity remain high [2]. With the discov-
ery of persistent critical illness among sepsis survivors,
new challenges regarding the syndrome have also
emerged, implying that specific treatments are still greatly
in demand [3]. However, the complex pathophysiology of
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sepsis makes this difficult [4]. Sepsis is now regarded as a
failure of homeostasis at all levels, from intracellular sig-
naling systems to overall organ function, characterized by
a loss of specialized cell function and barrier function
[5,6]. In this sense, it is no longer a uniquely immune-
mediated disease.
However, the innate immune system is crucial for ini-
tial pathogen recognition and response, leading to sys-
temic inflammation that disrupts homeostasis. The
complement system and the Toll-like receptors (TLRs)
with its coreceptor CD14 plays pivotal roles in sepsis as
key, upstream molecules of innate immunity recognizing
danger [7–9]. The coagulation system is also closely
linked to the complement system, and consumptive
coagulopathy is a hallmark of severe sepsis
[10–12]. Indeed, coincident coagulation and inflammation
– immunothrombosis – has been postulated to be a
physiological phenomenon of the microvasculature in
response to danger [12]. Ekdahl et al. recently coined the
term thromboinflammation, designating the collective
activation of innate immunity and coagulation [13]. In
sepsis, tissue factor (TF) is the main initiator of coagula-
tion, and dysfunctional anticoagulation and impaired fib-
rinolysis further potentiate coagulation, resulting in
consumptive coagulopathy [6,14]. Therefore, it is impor-
tant to note that complement activation is known to
induce TF expression [15–17].
We have previously shown that early, upstream inhibi-
tion of innate immunity efficiently reduces the levels of
key inflammatory mediators whose levels are otherwise
increased in response to, for example, Escherichia coli and
Staphylococcus aureus [18–20].
We here hypothesize that TF expression is a down-
stream event of complement and TLR activation, and
that combined inhibition of these systems will reduce
coagulation in response to S. aureus. This has been doc-
umented in our whole blood model with E. coli, in
which TF expression was largely complement-dependent
[21]. The present study focuses on Gram-positive spe-
cies, namely three pathogenic strains of S. aureus
(strains Cowan, Wood, and Newman), which is one of
the most commonly isolated bacteria in sepsis. S. aureus
is also particularly prone to inducing coagulation and
aggregation in blood [22,23]. We recently showed that
the staphylococci trigger the release of several important
cytokines related to TF expression and activation of
coagulation, such as interleukin (IL)-1b, IL-8, and
tumor necrosis factor, when added to human whole
blood [18,24,25]. The aims of this study were therefore
as follows: first, to investigate whether S. aureus induces
coagulation in human whole blood through a comple-
ment-dependent and/or a TLR-dependent increase in
TF expression; and second, to determine whether this
induction could be abrogated through inhibition of
complement and TLRs as a rationale for a future
therapy.
Materials and methods
Whole blood model of bacteremia
Whole blood experiments were performed with whole
blood from eight different donors and carried out as previ-
ously described [26]. In brief, blood drawn by venipuncture
was immediately distributed into polypropylene tubes con-
taining Dulbecco’s phosphate-buffered saline (PBS), inhibi-
tors, or controls. The samples were preincubated for 9 min
at 37 °C as described in the following. After preincubation,
PBS with CaCl2 and MgCl2 (Sigma-Aldrich, St Louis, MO,
USA), heat-inactivated S. aureus strains Cowan 1 (Ameri-
can Type Culture Collection [ATCC] 12598), Wood
(ATCC 10382) or Newman (ATCC 25904) were added to
a final whole blood concentration of 1 9 108 mL1. In the
dose–response experiments, 1 9 107 mL1, 3 9 107 mL1
and 1 9 108 mL1 were used. The bacteria were purchased
from the ATCC (Manassas, VA, USA).
The time zero (T0) sample was processed immediately
after blood sampling. After 60, 120 and 180 min of incu-
bation at 37 °C, blood was distributed into three different
sets of tubes. Two sets contained 3.2% citrate solution
(1 : 9 v/v), and the blood was used for flow cytometry
and TF functional analysis in plasma microparticles
(MPs). The last set contained EDTA (10 mM), and the
plasma was used for analysis by ELISA, and the cells of
the whole blood were used for quantitative PCR (qPCR).
The tubes were centrifuged for 15 min at 3220 9 g at
4 °C. Plasma was stored at  80 °C until it was analyzed.
Cell pellets were lysed and stabilized with PAXgene
reagent (PreAnalytiX, Qiagen, UK), and the lysates were
stored at  80 °C until mRNA analysis was performed.
The regional ethics committee of the Northern Norway
Regional Health Authority approved the study. All equip-
ment, tips and working solutions were endotoxin-free.
Lepirudin (Refludan; Celgene, Uxbridge, UK; 50 mg L1)
was used as the anticoagulant in polypropylene tubes
(4.5 mL; Nunc, Roskilde, Denmark).
Inhibitors and agonists
Anti-CD14 F(ab0)2 (lipopolysaccharide [LPS] concentra-
tion of < 3.9 EU mL1) was obtained from Diatec Mono-
clonals (Oslo, Norway), and added to a final
concentration of 10 lg mL1. The C3 convertase inhibi-
tor compstatin (lot CP20) and its corresponding control
peptide, synthesized as previously described [27], were
kind gifts from J. Lambris. Compstatin was used at a
final concentration of 20 lM. The C5 mAb eculizumab
(Soliris) was obtained from Alexion Pharmaceuticals
(Z€urich, Switzerland), and added to a final concentration
of 100 lg mL1. The cyclic hexapeptide PMX53 (se-
quence Ace-Phe-[Orn-Pro-dCha-Trp-Arg]), which blocks
C5a receptor 1 (C5aR1), was synthesized and purified as
previously described [28], and used at final concentration
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of 10 lM. The mouse anti-TF monoclonal blocking anti-
body (IgG1; Sekisui 4509) was obtained from American
Diagnostica (Pfungstadt, Germany), and the isotype-
matched control anti-HIV-1 gp120 (clone G3-519) was a
kind gift from M. Fung. Both were used at a final con-
centration of 5 lg mL1. Activated factor XII (FXIIa)-
blocking recombinant human albumin-infestin-4 (infestin)
was kindly provided by R. Spirig, CLS Behring (Mar-
burg, Germany), and its inhibitory effect was confirmed
by incubating lepirudin plasma in glass tubes for 60 min.
Uninhibited plasma generated 20 898  13 669 pmol L1
prothrombin fragment 1 + 2 (PTF1 + 2), whereas coincu-
bation with infestin reduced PTF1 + 2 levels to
975  464 pmol L1. The T2.5 monoclonal anti-TLR2
antibody was obtained from Hycult Biotech (Uden, the
Netherlands) and used at 10 lg mL1, whereas the
TLR4/MD2-blocking lipid A analog eritoran (E5564) was
obtained from Eisai (Andover, MA, USA) and used at
1 lM. The specific blocking of TLR2 and TLR4 with
T2.5 and eritoran, respectively, was confirmed by incubat-
ing whole blood with the respective agonists FSL-1
(50 ng mL1) and E. coli ultrapurified LPS
(100 ng mL1) from Invivogen (San Diego, CA, USA)
and the plasma tested for TNF (data not shown).
ELISAs
PTF1 + 2 plasma levels were measured with the Enzyg-
nost PTF1 + 2 (monoclonal) kit from Dade Behring
(Marburg, Germany). Human pentraxin 3 was analyzed
with an ELISA kit from R&D Systems (Minneapolis,
MN, USA). TF activity in plasma MPs was assayed with
the Zymuphen MP TF kit from Aniara (West Chester,
OH, USA), according to the kit insertions. Blood samples
were citrated and centrifuged at 1500 9 g for 15 min at
ambient temperature. Plasma was centrifuged at
13 000 9 g for 2 min, and supernatants were frozen at
 80 °C. In this assay, a mAb coated on the wells of the
microplate captures human TF without interfering with
the active site. Plasma is removed in a washing step, and
activated FVII and FX are introduced. Finally, an acti-
vated FX-specific substrate is added, producing a yellow
color. Soluble terminal complement complex (TCC) levels
(sC5b-9) were measured by use of a mAb against a C9
neoepitope specific for TCC, as previously described [29].
An MRX microplate reader (Dynex Technologies, Denk-
endorf, Germany) was used to measure ODs.
qPCR of TF mRNA levels
Total RNA was isolated with a MagMAX for Stabilized
Blood Tubes RNA Isolation kit. The RNA concentrations
were analyzed with a NanoDrop 2000c from Thermo
Fisher Scientific (Wilmington, DE, USA). The TF mRNA
levels were measured with the QuantStudio 6 Flex Real-
Time PCR System from Life Technologies (Carlsbad, CA,
USA). The TaqMan RNA-to-Ct 1 step kit (PN 4392938)
was used. Predeveloped TaqMan gene expression assays
were used for the target gene, i.e. the TF gene
(Hs00175225_m1), and the reference gene was the human
b2-microglobulin gene (assay ID 4326319E). The template
input was 4 ng of RNA, and the samples were analyzed
in triplicate. Plates (MicroAmp Fast 96-Well Reaction
Plate) were sealed with optical adhesive film (MicroAmp
Optical Adhesive film) by use of an applicator. The rela-
tive TF mRNA levels were measured with the compara-
tive D-D Ct method by the use of QUANTSTUDIO 6 FLEX
software. The TF mRNA levels in the samples after
120 min of incubation with PBS only were set to 1 and
used to calibrate the results. All reagents and consumables
were from Thermo Fisher Scientific.
Flow cytometric analysis of TF surface expression
Monocyte TF surface expression was quantified with a BD
LSR II flow cytometer (Becton Dickinson, San Jose, CA,
USA). Whole blood (12.5 lL) was stained with fluorescein
isothiocyanate (FITC)-conjugated anti-human TF (pro-
duct no. 4508CJ, clone VD8; American Diagnostica) and
phycoerythrin (PE)-conjugated anti-CD14 (Becton Dickin-
son) antibodies. IgG1 FITC (BD 345815) was used as an
isotype-matched control mAb. The blood was incubated
for 15 min at room temperature in the dark. Easy lyse
(S2364; Dako Cytomation, Glostrup, Denmark) was added
to the blood, which was incubated for another 15 min at
room temperature for erythrocyte lysis. The leukocytes
were washed with PBS with 0.1% (w/v) bovine serum albu-
min, and finally resuspended in PBS. Monocytes were
gated in a CD14 PE/side-scatter dot-plot, and the results
are reported as the median fluorescence intensity.
Colony-forming units (CFUs)
Blood was serially diluted in Dulbecco’s modified Eagle’s
medium/F-12 (Thermo Fisher), and 100 lL was evenly
distributed on a blood agar dish. The number of colonies
were counted on the following day, and the numbers were
corrected for the dilution.
Statistics and data presentation
The data were analyzed with GRAPHPAD PRISM 6.0h
(GraphPad Software, San Diego, CA, USA). Normality
was tested for with the Kolmogorov–Smirnov test, and
any non-normal or skewed data were log-transformed
before testing by one-way repeated measures ANOVA with
Dunnett’s post hoc test comparing all columns with that
of activated, uninhibited whole blood (the positive con-
trol), and comparing all columns with each other by the
use of Tukey’s multiple comparisons test. Sidak’s post hoc
test was used for the comparison between live and dead
bacteria. We assumed equal variability of variances, thus
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factoring out interindividual variations, for greater
power. Dose–response experiments were analyzed by use of
a two-way repeated measure ANOVA with Tukey’s multiple
comparisons test, and correlation was determined by
computing Pearson’s coefficient, r. Definitive outliers
(Q = 1%) were identified by ROUT (robust regression and
outlier removal), and one donor’s PTF1 + 2 levels in
response to the Wood strain were excluded. P-values of
< 0.05 were considered to be significant, and all graphs
show means and 95% confidence intervals as well as all
individual points.
Results
S. aureus-induced TF generation and coagulation are both
time-dependent and dose-dependent
TF mRNA levels and TF expression on monocytes
(which can be viewed as molecular assays of coagulation)
and the activity of TF in MPs (MP-TF) and the levels of
PTF1 + 2 (which can be viewed as functional assays of
coagulation) were all increased in response to experimen-
tal bacteremia (Fig. 1). They correlated with both increas-
ing doses of S. aureus Cowan strain (final concentrations
of 1 9 107, 3 9 107 and 1 9 108 mL1) and incubation
times (60, 120 and 180 min). The TF mRNA levels were
elevated at all time points as compared with the PBS con-
trol, and peaked at 120 min (Fig. 1, upper left panel).
TF surface expression increased steadily to 180 min,
and was greater than that in non-activated samples at all
time points (Fig. 1, upper right panel). The bacterial con-
centration of 1 9 108 mL1 induced higher levels than
1 9 107 mL1 at 60 min and 120 min, but not than
3 9 107 mL1 at 120 min and 180 min. MP-TF and
PTF1 + 2 levels were increased at 120 min and continued
to increase to 180 min in response to all three concentra-
tions of bacteria, although the differences between the
three concentrations were not statistically significant
(Fig. 1, lower right panel). On the basis of these findings,
we decided to use a final concentration of 1 9 108
staphylococci per milliliter of whole blood for an incuba-
tion time of 120 min in the following experiments.
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Fig. 1. Effects of Staphyloccus aureus Cowan on tissue factor (TF) upregulation and coagulation in human whole blood. TF mRNA levels, TF
surface expression on monocytes, the activity of TF in microparticles (MP-TF) and the levels of prothrombin fragment 1 + 2 (PTF1 + 2) were
all increased in response to S. aureus Cowan, and correlated with both increasing doses of bacteria (final concentrations 1 9 107, 3 9 107 and
1 9 108 mL1) and incubation times (60, 120 and 180 min). TF surface expression on monocytes was analyzed by flow cytometry, MP-TF with
an amidolytic assay, and PTF1 + 2 levels with ELISA. Data were obtained from six consecutive and independent experiments on blood from
six different donors, and are represented as means with 95% confidence intervals. *P < 0.05, when analyzed with repeated measures, two-way
ANOVA with Tukey’s multiple comparisons post hoc test, comparing means at 60, 120 and 180 min with each other. FI, fluorescence intensity;
PBS, phosphate-buffered saline; RQ, relative quantification.
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S. aureus induces high levels of complement and
coagulation activation products in human whole blood
Incubating three different strains of staphylococci in
human whole blood increased the levels of C5a, TCC, TF
mRNA, TF surface expression, MP-TF, and PTF1 + 2
(Table 1). The levels of the complement activation prod-
ucts C5a and TCC increased substantially (P < 0.01) in
response to the Cowan, Wood and Newman strains.
Total TF mRNA levels, TF surface expression on mono-
cytes, MP-TF levels and PTF1 + 2 levels also increased in
response to three strains. Collectively, the different
parameters increased five-fold to 55-fold, but the ratios of
the functional assays (MP-TF and PTF1 + 2) of coagula-
tion to the molecular assays (TF mRNA and TF surface
expression) were different between strains (Table 1). The
MP-TF/TF mRNA ratios were 2.6 for the Wood strain,
4.0 for the Cowan strain, and 11.0 for the Newman
strain. Likewise, the ratios of PTF1 + 2 levels to TF
mRNA levels and to TF surface expression, respectively,
were 1.1 and 0.9 for the Wood strain, 1.8 and 1.1 for the
Cowan strain, and 7.4 and 4.1 for the Newman strain.
This rank order was also seen for the ratios of MP-TF
and PTF1 + 2 levels to C5a and TCC levels, where the
Newman strain induced both the highest levels of comple-
ment activation products and the highest levels of MP-TF
and PTF1 + 2 (Table 1). In extension of this, C5a, TCC
and TF surface expression were all positively correlated
with MP-TF and PTF1 + 2 (Fig. 2, left panel). However,
little correlation was seen between TF mRNA levels and
MP-TF or PTF1 + 2 levels at 120 min.
Effect of inhibiting complement, CD14 or both on
coagulation in response to S. aureus
Whole blood was preincubated with the complement inhi-
bitors compstatin (C3) or eculizumab (C5), and a neutraliz-
ing anti-CD14 antibody alone or in combination with the
complement inhibitors, before a further 120 min of incuba-
tion with the Cowan strain (Fig. 3, upper two panels).
Complement activation as measured according to C5a
and TCC was completely abolished by compstatin and
eculizumab, indicating efficient complement inhibition,
whereas anti-CD14 had no effect on complement activa-
tion (Fig. 3, upper panels).
Eculizumab alone and both complement inhibitors
combined with anti-CD14 inhibited TF mRNA genera-
tion, whereas anti-CD14 and compstatin alone only
tended to do so (Fig. 3, middle left panel).
Both complement inhibitors inhibited TF expression,
and combining them with anti-CD14 enhanced this effect,
as combined inhibition with compstatin and anti-CD14
had a more pronounced effect on TF surface expression
than that obtained with either inhibitor alone (Fig. 3,
middle right panel). Notably, TF expression was the only
assay of coagulation that was inhibited to a statistically
significant extent by anti-CD14 alone.
Both complement inhibitors when used alone or in
combination with anti-CD14 inhibited MP-TF, whereas
anti-CD14 alone had no effect. The inhibitory effect of
eculizumab was stronger than that of compstatin.
Compstatin and eculizumab when used alone or in
combination with anti-CD14 reduced PTF1 + 2 levels.
The effect of eculizumab was more pronounced than that
of compstatin alone, and the effect of the combination of
eculizumab and anti-CD14 was more pronounced than
that of compstatin and anti-CD14 (Fig. 3, lower right
panel). Anti-CD14 did not affect PTF1 + 2 levels.
The results for the Wood strain (Fig. 4) were almost
identical to those described for the Cowan strain above.
Compstatin had a (statistically) stronger effect on TF
mRNA levels in response to the Wood strain (Fig. 4),
whereas the similar effect of anti-CD14 when used alone
on TF surface expression was only statistically significant
in response to the Cowan strain (Fig. 3).
The Newman strain (Fig. 5) induced greater responses
than the Cowan and Wood strains, but the effects of the
different inhibitors were similar with respect to comple-
ment activation, TF mRNA levels, TF surface expression,
and PTF1 + 2 levels. The inhibitory effects of either single
Table 1 Percentage upregulation of inflammatory and coagulation markers in response to Staphylococcus aureus strains Cowan, Wood and
Newman in human whole blood as compared with phosphate-buffered saline
Biomarker
Cowan Wood Newman
Fold change P-value Fold change P-value Fold change P-value
C5a (pg mL1) 19  3* 0.0007 16  2 0.0002 25  3 0.0002
TCC (AU mL1) 30  4 0.0004 24  5 0.0030 32  5 0.0017
TF mRNA (RQ) 6  1 0.0106 7  1 0.0038 5  4 0.0009
TF expression (MFI) 10  1 0.0008 9  1 0.0006 9  1 0.0016
MP-TF (pg mL1) 25  6 0.0069 18  3 0.0032 56  17 0.0232
PTF1 + 2 (pmol L
1) 11  3 0.0163 8  2 0.0258 37  14 0.0411
PTF1 + 2, prothrombin fragment 1 + 2; MFI, median fluorescence intensity; MP-TF, activity of tissue factor in microparticles; RQ, relative
quantification; TCC, terminal complement complex; TF, tissue factor. *Data are from six consecutive experiments in whole blood from six dif-
ferent donors (n = 6), and are presented as mean and standard error of the mean.
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or combined inhibition on MP-TF were less pronounced
and not statistically significant (Fig. 5).
In summary, for the experiments examining the activa-
tion of complement and coagulation after 120 min of
whole blood incubation with all three staphylococcal
strains, the combined inhibition of complement (either ecu-
lizumab or compstatin) and TLR (anti-CD14) reduced the
levels of 17 of the 18 (six per strain) parameters measured.
PTF1 + 2 was generated as a result of increased TF levels
To study whether coagulation, quantified as PTF1 + 2,
was mediated by TF, we conducted a second set of exper-
iments with a neutralizing anti-TF mAb. The anti-TF
mAb effectively reduced the S. aureus Cowan-induced,
Newman-induced and Wood-induced PTF1 + 2 levels
towards baseline values for all three strains (Fig. 6), con-
sistent with the correlated levels of complement-activation
products with increased MP-TF and PTF1 + 2 levels.
Importantly, PTF1 + 2 generation was not completely
abolished by blocking of TF. In a follow-up experiment
conducted in lepirudin-anticoagulated plasma, recombi-
nant TF induced PTF1 + 2 generation in a similar fash-
ion to the whole bacteria (Fig. 2, right panel). This
PTF1 + 2 generation was, in turn, completely abolished
both in the presence of anti-TF and in the presence of the
FXIIa inhibitor infestin.
C5aR1 blockade and TLR2 inhibition reduced complement
and coagulation comparably to combined inhibition of C5
and CD14 in response to S. aureus
Next, using S. aureus Cowan only, we explored whether
the effects of CD14 inhibition could be attributed to
TLR2 or TLR4, the two main CD14-dependent TLRs,
and whether the effects of complement inhibition could
be attributed to reduced activity in the C5a–C5aR1 axis.
TLR2 was inhibited by a mAb, TLR4 by eritoran, and
C5aR1 by PMX53.
TF mRNA levels, TF surface expression on mono-
cytes and MP-TF and PTF1 + 2 levels were measured.
Following the 120-min incubation, all four assays were
significantly (P < 0.05) and equally inhibited by the
C5aR1 antagonist and eculizumab (Fig. 7), indicating
that the complement effects were mediated through
C5aR1 activation.
Anti-TLR2 alone significantly reduced TF expression
on monocytes but not the levels of the other three mark-
ers of coagulation, consistent with the results obtained
with anti-CD14 (Fig. 7; also shown in Fig. 3). The addi-
tion of a complement inhibitor also enhanced the effect
of CD14 or TLR2 inhibition on TF expression, but no
additional effects of anti-CD14 or anti-TLR2 were seen
on the other three markers.
Staphylococcal loads were reduced during the whole blood
experiments, and the effects of complement inhibition were
identical to the responses induced by both live and dead
bacteria
First, we examined CFUs of live S. aureus. We observed
a decrease in the number of S. aureus CFU from 0 min
to 120 min (Fig. S1). This reduction was less pronounced
when eculizumab was used than when the other inhibitors
were used. Second, we compared live and dead S. aureus.
Live S. aureus generated greater levels of PTF1 + 2 than
dead bacteria, whereas the levels of TF mRNA, TF sur-
face expression and MP-TF increased comparably in
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response to both live and dead bacteria (Fig. S2). Like-
wise, the effects of the different inhibitors on these
responses were almost identical for both live and dead
bacteria, except for a somewhat more pronounced effect
of complement inhibition on TF surface expression in
response to dead bacteria. Finally, inhibiting TF, but not
FXIIa, inhibited the PTF1 + 2 generation in response to
both live and dead bacteria, whereas TF mRNA levels,
surface expression of TF and MP-TF were unaffected by
both TF and FXIIa blockade (Fig. S2).
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levels of complement fragment C5a and terminal complement complex (TCC) in plasma, and tissue factor (TF) mRNA, monocyte surface
expression of TF, TF activity in microparticles (MP-TF) and prothrombin fragment 1 + 2 (PTF1 + 2) levels in humans after 120 min of incu-
bation as compared with the phosphate-buffered saline (PBS) control. All of these were reduced towards baseline levels when whole blood was
preincubated with the C5-inhibitory antibody eculizumab (Eculiz.). The C3-inhibitory peptide compstatin (Comp.) attenuated the levels of C5a,
TCC and TF monocyte surface expression only. The anti-CD14 antibody (aCD14) reduced TF surface expression, and this affect was potenti-
ated by using one of the two complement inhibitors. The rightmost column (control) represents stimulated whole blood preincubated with PBS
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dence intervals and all points shown. *P < 0.05, when analyzed with repeated measures, one-way ANOVA with Dunnett’s and Tukey’s multiple
comparisons post hoc tests. CAU, complement activating units; Ctrl, control; FI, fluorescence intensity; RQ, relative quantification.
© 2018 The Authors. Journal of Thrombosis and Haemostasis published by Wiley Periodicals, Inc. on behalf of International Society on
Thrombosis and Haemostasis.
S. aureus coagulates blood through complement activation 911
Discussion
In this study, we have documented time-dependent and
dose-dependent coagulation in human whole blood in
response to three different strains of S. aureus, isolated
from human infections. We revealed that this coagulation
occurs through early and upstream complement-depen-
dent increases in TF expression and activity, subsequently
leading to downstream coagulation with the release of
PTF1 + 2. Complement inhibition at the level of C5,
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Fig. 4. Responses to Staphylococcus aureus Wood in human whole blood. Heat-inactivated S. aureus Wood (1 9 108 mL1) increased the levels
of complement fragment C5a and terminal complement complex (TCC) in plasma, and tissue factor (TF) mRNA, monocyte surface expression
of TF, TF activity in microparticles (MP-TF) and prothrombin fragment 1 + 2 (PTF1 + 2) levels in human whole blood after 120 min of incu-
bation as compared with the phosphate-buffered saline (PBS) control. All of these were reduced towards baseline levels when whole blood was
preincubated with either the C3-inhibitory peptide compstatin (Comp.) or the C5-inhibitory antibody eculizumab (Eculiz.), as well as by the
combination of either compstatin or eculizumab with the anti-CD14 antibody (aCD14). Although aCD14 exerted no inhibitory effect on its
own, combined inhibition with compstatin and aCD14 had a significantly stronger effect on TF surface expression than compstatin alone. The
rightmost column (control) represents stimulated whole blood preincubated with PBS containing control peptide and control antibody. Data
were from six consecutive and independent experiments using blood from six different donors, and are represented as columns to the means with
95% confidence intervals and all points shown. The TF mRNA levels were from four donors, as two samples were lost in analysis, and the
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way ANOVA with Dunnett’s and Tukey’s multiple comparisons post hoc tests. Ctrl, control; FI, fluorescence intensity; RQ, relative quantification.
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confirmed to be mediated through C5aR1, efficiently
attenuated coagulation, particularly when C5 inhibition
was combined with CD14 and TLR2 inhibition. Although
complement-dependent upregulation of TF has been doc-
umented before [15–17], we show that the complement-
mediated coagulation via TF in response to S. aureus can
be efficiently reduced by inhibiting complement, suggest-
ing that it is an important mechanism with clinical rele-
vance and therapeutic potential.
In line with our previous study of S. aureus-induced
cytokine release in whole blood [18], TF expression was
largely complement-dependent. Blockade of the TLR
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Fig. 5. Responses to Staphylococcus aureus Newman in human whole blood. Heat-inactivated S. aureus Newman (1 9 108 mL1) increased the
levels of complement fragment C5a and terminal complement complex (TCC) in plasma, and tissue factor (TF) mRNA, monocyte surface
expression of TF, TF activity in microparticles (MP-TF) and prothrombin fragment 1 + 2 (PTF1 + 2) levels in humans after 120 min of incu-
bation as compared with the phosphate-buffered saline (PBS) control. All of these, except for MP-TF, were reduced towards baseline levels
when whole blood was preincubated with the C5-inhibitory antibody eculizumab (Eculiz.). The C3-inhibitory peptide compstatin (Comp.)
attenuated the levels of C5a, TCC and MP-TF only. The anti-CD14 antibody (aCD14) exerted no inhibitory effect on its own. The rightmost
column (control) represents stimulated whole blood preincubated with PBS containing control peptide and control antibody. Data were from
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coreceptor CD14 exerted very little effect on its own,
indicating that CD14 is generally more important as a
coreceptor in the immunological response induced by
Gram-negative bacteria [30]. However, anti-CD14 did
reduce the monocyte surface expression of TF in response
to the Cowan strain, in line with previous findings
obtained with LPS [31], indicating that there is also some
cross-talk between TLRs and coagulation in response to
Gram-positive bacteria. Anti-TLR2 exerted similar effects
as anti-CD14, as shown by the responses to specific
TLR2 agonists [30], as well as staphylococcal exotoxins
[32] and the Cowan strain used in this study [33]. In con-
trast to TLR2 inhibition, TLR4 inhibition did not affect
coagulation in our study. However, both CD14 and
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Fig. 6. Effect of a neutralizing anti-tissue factor antibody on Staphylococcus aureus-induced coagulation in human whole blood. Heat-inacti-
vated S. aureus (1 9 108 mL1) increased prothrombin fragment 1 + 2 (PTF1 + 2) levels when added to human whole blood after 120 min of
incubation as compared with the phosphate-buffered saline (PBS) control. The levels were reduced towards baseline levels by preincubating the
whole blood with a neutralizing mAb against tissue factor (aTF). The rightmost column (Ctrl) represents whole blood incubated with an iso-
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complement are involved in Gram-positive and Gram-
negative bacteremia, and our data indicate that combined
inhibition of complement and CD14/TLR2 broadly atten-
uates the downstream effects of S. aureus bacteremia with
regard to both inflammation and coagulation. Indeed,
CD14 is a documented coreceptor for TLR2, underscor-
ing it as a suitable target for broad inhibition of TLR
activation [34].
Apparently, compstatin had a less pronounced effect
on reducing coagulation than eculizumab. However, an
older version of compstatin (CP20) was used in this
study, and it is reasonable to suggest that the somewhat
lesser effect is attributable to some remnant C3 activity,
generating small amounts of C5a leading to coagulation.
Given the consistent effect of C5 inhibition on coagula-
tion, we argue that C5a is the main inducer of TF genera-
tion. Furthermore, as both eculizumab and PMX53
efficiently and equally reduced the levels of TF and coag-
ulation, we argue that coagulation is mainly driven by
activation of the C5a–C5aR1 axis. Importantly, we docu-
ment that the PTF1 + 2 generation seen in response to
S. aureus is caused by a complement-dependent increase
in TF expression, mediated by thrombin generation,
whereas the contact-dependent pathway of coagulation at
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Fig. 7. Effects of selective C5a receptor 1, C5, Toll-like receptor (TLR) 2 and CD14 inhibition on Staphylococcus aureus-induced tissue factor
(TF) generation and coagulation in human whole blood. Heat-inactivated S. aureus Cowan (1 9 108 mL1) increased TF mRNA, monocyte TF
surface expression, TF activity in microparticles (MP-TF) and prothrombin fragment 1 + 2 (PTF1 + 2) levels in human whole blood after
120 min of incubation as compared with the phosphate-buffered saline (PBS) control. All of these were reduced towards baseline levels when
whole blood was preincubated with either the C5-inhibitory antibody eculizumab (Eculiz.) or the C5a receptor 1 antagonist (C5aRag). Both the
anti-CD14 antibody (aCD14) and the anti-TLR2 mAb (aTLR2) significantly reduced the levels of TF expression on monocytes, but not any
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the level of FXIIa is not involved. Likewise, the increased
levels of PTF1 + 2 were efficiently reduced by the neutral-
izing anti-TF mAb, which returned PTF1 + 2 levels back
towards baseline. Also, PTF1 + 2 generation was both
correlated with TF expression on monocytes, and induced
by recombinant TF, underscoring that TF was the main
driver of coagulation. We also show that this is the case
for live staphylococci (Cowan strain).
However, the substantial but incomplete blockade of
PTF1 + 2 in response to S. aureus, as well as the varia-
tion between the molecular and functional assays of coag-
ulation in response to the different strains, suggest that
the functional assays of coagulation activation (although
TF-driven, as shown in Fig. 5) are systematically sensitive
to some factor other than TF expression. Indeed, the
Newman strain, which also had the greatest impact on
complement activation as quantified by the TCC/C5a
ratio, generated the greatest amount of PTF1 + 2. Also,
TF inhibition completely blocked PTF1 + 2 generation in
response to recombinant TF in lepirudin-anticoagulated
plasma, whereas some remnant PTF1 + 2 generation was
apparent in response to the bacteria in whole blood. Col-
lectively, these findings indicate that complement activa-
tion enhances the functional coagulation measurements,
possibly by decryption of TF, or perhaps more likely by
generating more procoagulant negatively charged phos-
pholipid membrane via activation of platelets or mono-
cytes. FXIIa inhibition, however, did not affect PTF1 + 2
levels, indicating that contact activation is not involved,
but potential activation of FXI and FIX by serine pro-
teases of the complement system cannot be ruled out.
A justified objection to our claims concerns the limita-
tions of our whole blood model, which must be fully
acknowledged. First, the human whole blood model is
limited both in time and place by the absence of endothe-
lium, blood flow, replenished cellular components, and
acute-phase reactants. Second, lepirudin specifically
blocks thrombin, both limiting the available assays of
coagulation and masking the contributions of thrombin
itself. Thrombin has been postulated to activate comple-
ment directly [35], although a very recent study performed
in septic baboons did not detect any complement activa-
tion by thrombin (or plasmin) [36]. Likewise, the recent
focus on the cross-talk between the many plasma cascade
systems in thromboinflammation has revealed that throm-
bin can affect both platelet and endothelial cell function
[13]. Another objection concerns the time of intervention,
as the potential ‘treatment’ is added before the ‘disease’ is
induced by the bacteria.
However, our whole blood model leaves all other
plasma cascade systems and blood cells intact, and thus
gives a holistic picture of the responses that we argue can
be seen at localized foci of infection, where pathogens
constantly interact with complement and TLRs, including
the important CD14 molecule. This is an obvious strength
as compared with isolated cell systems, for example.
Equally, the high amounts of staphylococci used may
exceed the concentrations seen systemically, but may be
apparent at localized sites of infection. Comparable
amounts of bacteria have been measured in the clinic
through qPCR [37,38], although studies aimed at quanti-
fying the bacteremia in sepsis are generally lacking [39].
Indeed, it would be interesting to establish more com-
plex models of staphylococcal infection and sepsis, and to
examine clinical cases, to verify our findings. Likewise, it
is important to examine the role of platelets more closely,
as this was beyond the scope of the present study. Thus
far, our findings corroborate and extend the scope of ear-
lier studies documenting coagulation downstream of com-
plement activation [15–17,40]. We here document
coagulation in response to complement activation induced
by staphylococci. In turn, this can allow us to better
assess the responses to S. aureus in larger, more complex
and life-like models, ultimately leading to new therapeutic
alternatives.
Conclusion
In conclusion, the inhibition of complement reduced the
otherwise powerful coagulation in response to three dif-
ferent strains of staphylococci. The S. aureus-induced
coagulation in human whole blood was chiefly attributa-
ble to C5aR1 activation, although TLR2 and its corecep-
tor CD14 contributed to the increased surface expression
of TF on monocytes. These data underscore complement
as a key player in S. aureus-induced coagulation, and
complement inhibition could potentially limit S. aureus-
induced thromboinflammation and full-blown sepsis.
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